Fig. 1: Prediction of patient-specific neopeptides. | Nature Communications

Fig. 1: Prediction of patient-specific neopeptides.

From: Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Fig. 1

a Overview of workflow for identification and prediction of mutation-derived neopeptides in mUC patients. Created with BioRender.com. b Number of predicted and HLA-feasible neopeptides with EL%Rank <0.5, and TMB (diamond) in the patient cohort. Patients grouped according to best RECIST 1.1 criteria, PD (n = 13 patients; median = 123, range = 16–700 neopeptides with EL%Rank <0.5 predicted) and SD/PR/CR patients (n = 11 patients; median = 292, range = 26–898 neopeptides with EL%Rank <0.5 predicted). Dotted line represents minimum 200 neopeptides included in panel for each patient. c, d TMB and number of prediced neopeptides with EL%Rank <0.5 for patients with PD compared to SD/PR/CR patients. For (c, d) groups were compared using non-parametric two-sided Mann–Whitney test and data is presented as median values ± largest/smallest value within upper/lower quartile ± 1.5 IQR. NS. Not Significant. Source data are provided as a Source Data file.

Back to article page